Version 1
: Received: 25 March 2024 / Approved: 26 March 2024 / Online: 26 March 2024 (14:17:01 CET)
How to cite:
Latalska, M.; Dresler, S.; Rejdak, R. Panmacular Micropulse Laser Treatment of Central Serous Chorioretinopathy: Two-Year Follow-Up of Morphological and Functional Parameters. Preprints2024, 2024031584. https://doi.org/10.20944/preprints202403.1584.v1
Latalska, M.; Dresler, S.; Rejdak, R. Panmacular Micropulse Laser Treatment of Central Serous Chorioretinopathy: Two-Year Follow-Up of Morphological and Functional Parameters. Preprints 2024, 2024031584. https://doi.org/10.20944/preprints202403.1584.v1
Latalska, M.; Dresler, S.; Rejdak, R. Panmacular Micropulse Laser Treatment of Central Serous Chorioretinopathy: Two-Year Follow-Up of Morphological and Functional Parameters. Preprints2024, 2024031584. https://doi.org/10.20944/preprints202403.1584.v1
APA Style
Latalska, M., Dresler, S., & Rejdak, R. (2024). Panmacular Micropulse Laser Treatment of Central Serous Chorioretinopathy: Two-Year Follow-Up of Morphological and Functional Parameters. Preprints. https://doi.org/10.20944/preprints202403.1584.v1
Chicago/Turabian Style
Latalska, M., Sławomir Dresler and Robert Rejdak. 2024 "Panmacular Micropulse Laser Treatment of Central Serous Chorioretinopathy: Two-Year Follow-Up of Morphological and Functional Parameters" Preprints. https://doi.org/10.20944/preprints202403.1584.v1
Abstract
Aim: To evaluate the panmacular subthreshold micropulse laser treatment results among patients with central serous chorioretinopathy (CSC) and their correlation with functional and morphological parameters. Material and methods: The examined group included 10 non-treated and 41 treated patients with acute, recurrent, and chronic CSC (13 F, 38 M, mean age 44.11±6.5) and 14 healthy controls (6 F, 8 M, mean age 45±9.3). The BCVA examination, ophthalmoscopy, microp-erimetry, angio-OCT and OCT were performed. The medical history regarding chronic general disorders and known risk factors were recorded. Results: Complete resorption of SRF was obtained in 100% aCSC, 86.66% cCSC, and 63.63% r CSC. BCVA and RetSens significantly improved most of the patients treated in aCSC. The lowest BCVA and RetSens, but the largest pachyvessel and disease duration, were found in rCSC. A strong negative correlation between final BCVA and disease duration was found. No patient demonstrated laser lesions following treatment. Conclusions: The panmacular MPLT therapy leads to long-term enhancement of functional and morphological parameters in all CSC patients. The acute CSC patients showed the most significant improvement. The procedure is safe and could be considered a preferred treatment option for all active CSC cases. Timely treatment is crucial for beneficial outcomes.
Keywords
panmacular micropulse laser treatment; central serous chorioretinopathy; choroidal thickness; pachyvessel; microperimetry; vessel density
Subject
Medicine and Pharmacology, Ophthalmology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
